SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C201 - Multiple Sclerosis Overview I: Clinical Pearls

Event Time: Thursday April 27, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s): Myla Goldman MD, MSC
Description: The first step in treating the MS patient is making the correct diagnosis. To do so, one must understand the spectrum of presentations, such as first episode or MRI-only forms of MS (clinically isolated syndrome and radiologically isolated syndrome). Clinicians should also recognize alternative diagnoses or “MS mimics.” MRI is an essential tool in the early stages of diagnosis and over the course of a patient's care and management. Clinicians need to thoughtfully use MRI to monitor patients and guide decisions about when and if to change treatment. Faculty will review basic pathophysiology and risk factors in MS, common differential diagnostic considerations, clinical MRI tools and applications in the context of MS diagnosis and determination of treatment response. This program complements C190: Multiple Sclerosis Overview: Basic and Translational Science and C214: Multiple Sclerosis Overview: Clinical Advances, but covers independent topics.
Completion Message: Participants should be able to feel comfortable diagnosing MS and excluding clinically appropriate differential diagnoses, have increased confidence in using clinical MRI tools, and have a strategy for integrating this into their MS practice.
CME Credits: 3
Core Competencies: Medical Knowledge, Patient Care

Program Speakers - Tentative

Start/End Time Title Faculty
1:00 PM - 1:45 PM MS Diagnosis and Classification Myla Goldman MD, MSC 
1:45 PM - 2:00 PM Questions and Answers Myla Goldman MD, MSC 
2:00 PM - 2:45 PM MRI and MS: Is a Picture Worth a Thousand Words? Scott Newsome DO, FAAN 
2:45 PM - 3:00 PM Questions and Answers Scott Newsome DO, FAAN 

Disclosures

Speaker Disclosure
Myla D. Goldman, MD, MSC Compensation from Genzyme and Novartis for consulting services and from Acorda Therapeutics, Biogen, Genzyme, and Novartis Pharmaceuticals for travel reimbursement. Institutional Consulting Contracts: Novartis, Biogen, Acorda (payment goes to UVA. Travel reimbursement to MDG when appropriate). Research support from Biogen, Novartis Pharmaceuticals, NMSS and NINDS.

Scott Douglas Newsome, DO, FAAN Dr. Newsome has received personal compensation for activities with Biogen Idec, Novartis, and Genzyme.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?